New hope for HPV-linked head and neck cancer: early trial tests targeted therapy
NCT ID NCT03978689
First seen Jan 24, 2026 · Last updated May 21, 2026 · Updated 17 times
Summary
This early-phase study tested a new drug called CUE-101, alone or with pembrolizumab, in 80 adults with HPV16-positive head and neck cancer that had spread or returned. The main goals were to check safety and find the right dose. Researchers also looked at how well the drug shrank tumors. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Oncologists, LLC
Chicago, Illinois, 33612, United States
-
Barbara Karmanos Cancer Center/ Wayne State University School of Medicine
Detroit, Michigan, 48201, United States
-
Emory University School of Medicine
Atlanta, Georgia, 30322, United States
-
Gabrail Cancer Center
Canton, Ohio, 44718, United States
-
George Washington University Cancer Center
Washington D.C., District of Columbia, 20037, United States
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 20231, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10017, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Stanford University Medical Center
Palo Alto, California, 94305, United States
-
University of Arizona
Tucson, Arizona, 85719, United States
-
University of Michigan
Ann Arbor, Michigan, 48197, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Washington School of Medicine
Seattle, Washington, 98195, United States
-
Vanderbilt-Ingram Cancer Center (VICC)
Nashville, Tennessee, 37232, United States
-
Washington University
St Louis, Missouri, 63110, United States
-
Yale School of Medicine
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.